Watson and Natco sign a licensing deal for a generic Revlimid

12/7/2010 | Bloomberg Businessweek

Natco Pharma granted Watson Pharmaceuticals domestic development and marketing rights to lenalidomide, a generic version of Celgene's multiple myeloma treatment Revlimid. The agreement entitles Watson to a share of sales profit. Natco is expected to be the first company to file for approval of a generic Revlimid.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL